Identification of anti-cancer natural compounds against colchicine binding site of tubulin: a combined structure and QSAR-based approach
暂无分享,去创建一个
S. Sahu | K. Ojha | V. Singh | Rakesh Kumar
[1] A. Olğaç,et al. Novel Indole-Pyrazole Hybrids as Potential Tubulin-Targeting Agents; Synthesis, antiproliferative evaluation, and molecular modeling studies. , 2023, Journal of molecular structure.
[2] M. Hawash. Recent Advances of Tubulin Inhibitors Targeting the Colchicine Binding Site for Cancer Therapy , 2022, Biomolecules.
[3] I. Banerjee,et al. Molecular dynamics simulations, docking and MMGBSA studies of newly designed peptide-conjugated glucosyloxy stilbene derivatives with tumor cell receptors , 2022, Molecular Diversity.
[4] A. Olğaç,et al. Design and Synthesis of Novel Substituted Indole-acrylamide Derivatives and Evaluation of Their Anti-Cancer Activity as Potential Tubulin-Targeting Agents , 2022, Journal of Molecular Structure.
[5] Guilherme Martins Silva,et al. Potential colchicine binding site inhibitors unraveled by virtual screening, molecular dynamics and MM/PBSA , 2021, Comput. Biol. Medicine.
[6] Aiping Lu,et al. ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties , 2021, Nucleic Acids Res..
[7] A. A. Al-karmalawy,et al. Revisiting Activity of Some Nocodazole Analogues as a Potential Anticancer Drugs Using Molecular Docking and DFT Calculations , 2021, Frontiers in Chemistry.
[8] A. Shiroudi,et al. Theoretical investigations on the HOMO–LUMO gap and global reactivity descriptor studies, natural bond orbital, and nucleus-independent chemical shifts analyses of 3-phenylbenzo[d]thiazole-2(3H)-imine and its para-substituted derivatives: Solvent and substituent effects , 2021 .
[9] Daiying Zuo,et al. MAY, a novel tubulin inhibitor, induces cell apoptosis in A549 and A549/Taxol cells and inhibits epithelial-mesenchymal transition in A549/Taxol cells. , 2020, Chemico-biological interactions.
[10] N. O’Boyle,et al. Colchicine-Binding Site Inhibitors from Chemistry to Clinic: A Review , 2020, Pharmaceuticals.
[11] Denis Fourches,et al. Inductive transfer learning for molecular activity prediction: Next-Gen QSAR Models with MolPMoFiT , 2019, Journal of Cheminformatics.
[12] Yang Jiao,et al. Identification of novel and potent small-molecule inhibitors of tubulin with antitumor activities by virtual screening and biological evaluations , 2019, J. Comput. Aided Mol. Des..
[13] D. Arthur,et al. A Derived QSAR Model for Predicting Some Compounds as Potent Antagonist against Mycobacterium tuberculosis: A Theoretical Approach , 2019, Advances in preventive medicine.
[14] S. Patel,et al. The Role of Colchicine in Acute Coronary Syndromes. , 2019, Clinical therapeutics.
[15] Madhuri Pola,et al. In silico modelling and molecular dynamics simulation studies on L-Asparaginase isolated from bacterial endophyte of Ocimum tenuiflorum. , 2018, Enzyme and microbial technology.
[16] E. Márquez,et al. Molecular modeling studies of bromopyrrole alkaloids as potential antimalarial compounds: a DFT approach , 2018, Medicinal Chemistry Research.
[17] D. Sackett,et al. Colchicine: an ancient drug with novel applications , 2018, The British journal of dermatology.
[18] Abdullah M. Asiri,et al. Podophyllotoxin derivatives as an excellent anticancer aspirant for future chemotherapy: A key current imminent needs. , 2018, Bioorganic & medicinal chemistry.
[19] Ke Li,et al. Design, synthesis and biological evaluation of 2-phenylquinoline-4-carboxamide derivatives as a new class of tubulin polymerization inhibitors. , 2017, Bioorganic & medicinal chemistry.
[20] Daiying Zuo,et al. BZML, a novel colchicine binding site inhibitor, overcomes multidrug resistance in A549/Taxol cells by inhibiting P-gp function and inducing mitotic catastrophe. , 2017, Cancer letters.
[21] Ritu Jain,et al. GQSAR modeling and combinatorial library generation of 4-phenylquinazoline-2-carboxamide derivatives as antiproliferative agents in human Glioblastoma tumors , 2017, Comput. Biol. Chem..
[22] A. Eastman,et al. Microtubule destabilising agents: far more than just antimitotic anticancer drugs , 2017, British journal of clinical pharmacology.
[23] M. M. Rizvi,et al. Pharmacophore modeling, 3D-QSAR, docking study and ADME prediction of acyl 1,3,4-thiadiazole amides and sulfonamides as antitubulin agents , 2016 .
[24] Y. Zhen,et al. A Novel Nitrobenzoate Microtubule Inhibitor that Overcomes Multidrug Resistance Exhibits Antitumor Activity , 2016, Scientific Reports.
[25] B. Gigant,et al. Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery , 2016, The FEBS journal.
[26] Ya-Juan Qin,et al. Combined Molecular Docking, 3D‐QSAR, and Pharmacophore Model: Design of Novel Tubulin Polymerization Inhibitors by Binding to Colchicine‐binding Site , 2015, Chemical biology & drug design.
[27] Berk Hess,et al. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers , 2015 .
[28] Duane D. Miller,et al. Structural Optimization of Indole Derivatives Acting at Colchicine Binding Site as Potential Anticancer Agents. , 2015, ACS medicinal chemistry letters.
[29] Supratik Kar,et al. On a simple approach for determining applicability domain of QSAR models , 2015 .
[30] David A. Winkler,et al. Beware of R2: Simple, Unambiguous Assessment of the Prediction Accuracy of QSAR and QSPR Models , 2015, J. Chem. Inf. Model..
[31] Jigar A. Makawana,et al. Discovery and molecular modeling of novel 1-indolyl acetate--5-nitroimidazole targeting tubulin polymerization as antiproliferative agents. , 2014, European journal of medicinal chemistry.
[32] Rajendra Kumar,et al. g_mmpbsa - A GROMACS Tool for High-Throughput MM-PBSA Calculations , 2014, J. Chem. Inf. Model..
[33] K. Rohini,et al. Molecular Dynamics Simulations and Principal Component Analysis on Human Laforin Mutation W32G and W32G/K87A , 2014, The Protein Journal.
[34] J. Dhanjal,et al. Mechanistic insights into mode of action of novel natural cathepsin L inhibitors , 2013, BMC Genomics.
[35] Xiao‐Feng Wang,et al. N-aryl-6-methoxy-1,2,3,4-tetrahydroquinolines: a novel class of antitumor agents targeting the colchicine site on tubulin. , 2013, European journal of medicinal chemistry.
[36] J. Díaz,et al. The binding sites of microtubule-stabilizing agents. , 2013, Chemistry & biology.
[37] P. R. Sharma,et al. Novel indole-bearing combretastatin analogues as tubulin polymerization inhibitors , 2013, Organic and medicinal chemistry letters.
[38] Duane D. Miller,et al. An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site , 2012, Pharmaceutical Research.
[39] Maria Kavallaris,et al. Microtubules and resistance to tubulin-binding agents , 2010, Nature Reviews Cancer.
[40] R. Boggia,et al. Genetic algorithms as a strategy for feature selection , 1992 .
[41] K. Ojha. Development of predictive in silico cytotoxic activity model to predict the cytotoxicity of a diverse set of colchicine binding site inhibitors , 2022, Eurasian Journal of Medicine and Oncology.
[42] Chaoyang Zhang,et al. A Review of Feature Reduction Methods for QSAR-Based Toxicity Prediction , 2019, Challenges and Advances in Computational Chemistry and Physics.
[43] S. Emami,et al. New thiazole-2(3H)-thiones containing 4-(3,4,5-trimethoxyphenyl) moiety as anticancer agents. , 2019, European journal of medicinal chemistry.
[44] Duane D. Miller,et al. A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance. , 2018, Cancer research.
[45] S. Ahmadi,et al. QSAR Modeling of the Arylthioindole Class of Colchicine Polymerization Inhibitors as Anticancer Agents. , 2017, Current computer-aided drug design.
[46] E. Nogales. Structural insights into microtubule function. , 2000, Annual review of biochemistry.